For in vitro diagnostic use. Others OXY IVD OXY CPS_000193 Oxycodone 09026916190 OXY, 200T, cobas c pack green, PCh OXY 07613336190791 Reagents, kits 200 tests cobas c 303/503 true 08321248190 OXY, 200T, cobas c, Int, PCh OXY 07613336154045 Reagents, kits 200 tests COBAS INTEGRA 400 Plus, cobas c 311/501/502 true 0209026916190c503 OXY Oxycodone en 3 FF00000005A6520E FF000000050C990E 09026916190 9493 cobas c 303 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use DRI Oxycodone assay (OXY) is an in vitro diagnostic test for the semiquantitative and qualitative detection of oxycodone in human urine at cutoff concentrations of 100 ng/mL and 300 ng/mL on Roche/Hitachi cobas c systems.Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). DRI Oxycodone provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998.Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 0109026916190c503 OXY Oxycodone en 2 FF000000054F3E0E FF000000050E7B0E 09026916190 9493 cobas c 303 8481 cobas c 503 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use DRI Oxycodone assay (OXY) is an in vitro diagnostic test for the semiquantitative and qualitative detection of oxycodone in human urine at cutoff concentrations of 100 ng/mL and 300 ng/mL on Roche/Hitachi cobas c systems.Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). DRI Oxycodone provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998.Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 0008321248190COIN OXY Oxycodone en 2 FF00000005F5EC0E FF000000023B310E 08321248190 302 COBAS INTEGRA 400 plus Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useDRI Oxycodone assay (OXY) is an in vitro diagnostic test for the semiquantitative and qualitative detection of oxycodone in human urine at cutoff concentrations of 100 ng/mL and 300 ng/mL on COBAS INTEGRA systems.Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS).DRI Oxycodone provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998.Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en 0008321248190c501 OXY Oxycodone en 3 FF000000060D880E FF000000023B0B0E 08321248190 308 cobas c 311 2324 cobas c 502 309 cobas c 501 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended use DRI Oxycodone assay (OXY) is an in vitro diagnostic test for the semiquantitative and qualitative detection of oxycodone in human urine at cutoff concentrations of 100 ng/mL and 300 ng/mL on Roche/Hitachi cobas c systems.Semiquantitative test results may be obtained that permit laboratories to assess assay performance as part of a quality control program. Semiquantitative assays are intended to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as gas chromatography/mass spectrometry (GC‑MS). DRI Oxycodone provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. GC‑MS is the preferred confirmatory method.LREFKarch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press LLC 1998.Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are used. en